Erste Asset Management GmbH Sells 10,913 Shares of Axon Enterprise, Inc $AXON

Erste Asset Management GmbH lowered its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 94.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 594 shares of the biotechnology company’s stock after selling 10,913 shares during the period. Erste Asset Management GmbH’s holdings in Axon Enterprise were worth $425,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of AXON. Vanguard Group Inc. grew its stake in shares of Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after purchasing an additional 376,904 shares during the last quarter. Geode Capital Management LLC raised its position in Axon Enterprise by 5.9% during the 2nd quarter. Geode Capital Management LLC now owns 2,072,186 shares of the biotechnology company’s stock worth $1,713,332,000 after purchasing an additional 115,349 shares during the last quarter. Jennison Associates LLC lifted its holdings in Axon Enterprise by 53.8% during the 3rd quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock worth $677,412,000 after buying an additional 330,213 shares during the period. Vestor Capital LLC grew its position in shares of Axon Enterprise by 438,636.3% in the 2nd quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company’s stock valued at $690,170,000 after buying an additional 833,409 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Axon Enterprise in the second quarter valued at about $637,806,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Trading Down 1.4%

Shares of AXON stock opened at $542.40 on Monday. Axon Enterprise, Inc has a fifty-two week low of $396.41 and a fifty-two week high of $885.91. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53. The stock has a 50 day simple moving average of $537.92 and a two-hundred day simple moving average of $623.54. The company has a market cap of $43.61 billion, a P/E ratio of 356.84, a PEG ratio of 12.23 and a beta of 1.46.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping the consensus estimate of $1.60 by $0.55. The company had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company’s quarterly revenue was up 38.5% on a year-over-year basis. During the same quarter last year, the firm posted $2.08 EPS. Research analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insiders Place Their Bets

In other Axon Enterprise news, President Joshua Isner sold 20,000 shares of Axon Enterprise stock in a transaction on Monday, December 8th. The shares were sold at an average price of $552.60, for a total value of $11,052,000.00. Following the completion of the sale, the president directly owned 249,502 shares of the company’s stock, valued at approximately $137,874,805.20. The trade was a 7.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Jennifer H. Mak sold 1,134 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $600.00, for a total transaction of $680,400.00. Following the transaction, the chief accounting officer owned 13,740 shares in the company, valued at $8,244,000. This represents a 7.62% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 58,040 shares of company stock valued at $32,251,738. 5.70% of the stock is currently owned by corporate insiders.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on AXON shares. Needham & Company LLC lowered their price objective on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, February 20th. TD Cowen reissued a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Robert W. Baird set a $800.00 price target on shares of Axon Enterprise in a report on Wednesday. UBS Group dropped their price target on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Finally, Piper Sandler decreased their price objective on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $762.93.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.